Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict how patients will respond to treatment.

PURPOSE: This clinical trial is studying common genetic mutations related to mucositis in patients with multiple myeloma receiving high-dose melphalan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

NCT00991991

Melanoma (Skin)

TERMINATED

Molecular Genetics Studies of Cancer Patients and Their Relatives

NCT04185935

Malignant Neoplasm

RECRUITING

Study of DNA Samples From Patients With Multiple Myeloma

NCT00898040

Multiple Myeloma and Plasma Cell Neoplasm

COMPLETED

Collecting and Storing Blood Samples From Patients With Cancer

NCT00900120

Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia +8 more

WITHDRAWN

A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing

NCT02705404

Lung Neoplasms Carcinoma Non-small-cell Lung

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* To determine whether single nucleotide polymorphisms (SNPs) in genes that encode the melphalan transporters are associated with the development and/or severity of mucositis in patients with multiple myeloma receiving high-dose melphalan.
* To determine whether SNPs in genes that influence melphalan metabolism are associated with the development and/or severity of mucositis in these patients.

OUTLINE: This is a multicenter study.

Blood or mouthwash samples are collected and DNA isolated from these specimens is analyzed for single nucleotide polymorphisms (SNPs) in LAT1 or other candidate genes. Public databases (i.e., dbSNP and HapMap) are reviewed to select representative SNPs for genotype analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mucositis Multiple Myeloma and Plasma Cell Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Retrospective sample

People who have been diagnosed with multiple myeloma and have received high-dose melphalan.

laboratory biomarker analysis

Intervention Type OTHER

Blood or cheek cells wil be collected.

Prospective sample

People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.

laboratory biomarker analysis

Intervention Type OTHER

Blood or cheek cells wil be collected.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laboratory biomarker analysis

Blood or cheek cells wil be collected.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of multiple myeloma
* Receiving treatment with high-dose melphalan for an autologous stem cell transplantation at any of these facilities:

* Vanderbilt University Medical Center
* Nashville Veteran's Administration Medical Center (VAMC)
* Seattle VAMC
* San Antonio VAMC

PATIENT CHARACTERISTICS:

* Not pregnant

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No palifermin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No